论文部分内容阅读
目的:观察射频消融术(RFA)联合吉非替尼(Gefitinib)对晚期非小细胞肺癌(NSCLC)治疗的临床效果。方法:26例晚期NSCLC(III、IV期)患者用RFA联合Gefitinib治疗,与23例单独使用RFA治疗的对照组进行比较,观察两组之间有效率、生活质量和不良反应。结果:根据疗效、生活质量评分等指标进行评价,联合治疗组有效率为65.4%,高于单纯RFA治疗组的34.8%,两组之间有显著性差异(P<0.01),对接受治疗的患者进行生活质量评价结果表明,所有接受RFA和Gefitinib联合治疗组中有71.3%的病人生活质量良好,而接受单纯RFA治疗组中只有47%的患者生活质量良好,两组之间有显著性差异(P<0.01),两组患者不良反应主要是疼痛、发热、腹泻等,只需对症处理。结论:RFA联合Gefitinib综合治疗NSCLC方案优于单纯采用RFA的治疗方案。
Objective: To observe the clinical effect of radiofrequency ablation (RFA) combined with gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Twenty-six patients with advanced NSCLC (stage III, IV) were treated with RFA combined with Gefitinib and compared with 23 patients treated with RFA alone. The efficacy, quality of life and adverse reactions between the two groups were observed. Results: According to the indexes of curative effect and quality of life, the effective rate of combination therapy group was 65.4%, which was higher than that of RFA treatment group (34.8%), there was significant difference between the two groups (P <0.01) The quality of life assessment of patients showed that 71.3% of all patients receiving the combination of RFA and Gefitinib had a good quality of life, whereas only 47% of those receiving RFA alone had good quality of life with significant differences between the two groups (P <0.01). The adverse reactions in the two groups were mainly pain, fever, diarrhea and so on, only symptomatic treatment was needed. Conclusion: The combination of RFA and Gefitinib in the treatment of NSCLC is better than that of RFA alone.